 This research paper discusses the development of a novel type of photothermal agent, PDAs, which can be used to treat deep-seated tumors like osteosarcoma. The PDA is composed of three molecules, each with different properties. One molecule absorbs light in the near-infrared region and IRA, while another molecule absorbs light in the NR2 range. The third molecule is designed to convert the energy from the light absorbed by the other two molecules into heat. By changing the structure of the molecules, the researchers were able to shift the absorption peak from an IRA to an NR2, allowing them to use a laser beam at 1064 nm wavelength to activate the PDA. The PDA was then tested in vitro and in vivo, showing excellent results in terms of both cell viability and thermal damage. This article was authored by Zhensheng Shui, Hua Bai, Jiaxing Wu, and others.